IntroductionStudies of health utilities among people who use opioids have mostly been based on in‐treatment populations. We aim to report utility‐based quality of life by participants' socio‐demographic, drug and treatment characteristics, and to examine the determinants of health utility among people who use opioids regularly.MethodsCross‐sectional study of participants who used opioids regularly, recruited across New South Wales, Victoria and Tasmania in 2018–2019. Differences in European Quality of Life (EQ‐5D‐5L) heath utility scores between socio‐demographic and clinical subgroups were assessed using non‐parametric Kruskal–Wallis test by rank. To address the unique distribution of EQ‐5D‐5L health utility scores in the current sample, a two‐part model was applied to assess factors associated with health utility.ResultsAmong 402 participants enrolled in the study, 385 (96%) completed the EQ‐5D‐5L questionnaire. The mean health utility of the total sample was 0.63 (SD 0.29). Participants who previously received opioid agonist treatment [OAT] (adj marginal effect (ME) −0.11; 95% confidence interval [CI] −0.20 to −0.02) and those currently in OAT (adj ME −0.13; 95% CI −0.22 to −0.06) reported lower health utility than those who had never received OAT. Participants who used both pharmaceutical opioids and benzodiazepines had lower health utility compared to no pharmaceutical opioids and no benzodiazepines use (adj ME −0.17; 95% CI −0.28 to −0.07).Discussion and ConclusionsFindings provide important health utility data for economic evaluations, useful for guiding allocation of resources for treatment strategies among people who use opioids. Lower health utilities among those using benzodiazepines and pharmaceutical opioids suggests interventions targeting these subgroups may be beneficial.

中文翻译：

---

澳大利亚经常使用阿片类药物的人的健康效用

简介对阿片类药物使用者的健康效用的研究主要基于治疗人群。我们的目标是通过参与者的社会人口、药物和治疗特征来报告基于效用的生活质量，并检查定期使用阿片类药物的人的健康效用的决定因素。方法对定期使用阿片类药物的参与者进行横断面研究， 2018-2019 年新南威尔士州、维多利亚州和塔斯马尼亚州。使用非参数 Kruskal-Wallis 检验按等级评估社会人口学和临床亚组之间欧洲生活质量 (EQ-5D-5L) 健康效用评分的差异。为了解决当前样本中 EQ-5D-5L 健康效用分数的独特分布问题，采用两部分模型来评估与健康效用相关的因素。结果在参与该研究的 402 名参与者中，385 名 (96%) 完成了 EQ ‐5D-5L 问卷。总样本的平均健康效用为 0.63 (SD 0.29)。先前接受阿片类激动剂治疗的参与者[OAT]（调整边际效应（ME）-0.11；95%置信区间[CI]-0.20至-0.02）和目前接受OAT的参与者（调整ME -0.13；95% CI -0.22至−0.06）报告的健康效用低于那些从未接受过燕麦的人。与不使用阿片类药物和苯二氮卓类药物的参与者相比，同时使用阿片类药物和苯二氮卓类药物的参与者的健康效用较低（调整 ME -0.17；95% CI -0.28 至 -0.07）。 讨论和结论调查结果为经济评估提供了重要的健康效用数据，有用指导阿片类药物使用者治疗策略的资源分配。使用苯二氮卓类药物和阿片类药物的人群的健康效用较低，这表明针对这些亚组的干预措施可能是有益的。